BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36963813)

  • 1. Acceptability of multiple coated mini-tablets in comparison to syrup in infants and toddlers: a randomised controlled study.
    Klingmann V; Hinder M; Langenickel TH; Chen F; Khder Y; Breitkreutz J; Bosse HM
    Arch Dis Child; 2023 Sep; 108(9):730-735. PubMed ID: 36963813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acceptability of small-sized oblong tablets in comparison to syrup and mini-tablets in infants and toddlers: A randomized controlled trial.
    Münch J; Meissner T; Mayatepek E; Wargenau M; Breitkreutz J; Bosse HM; Klingmann V
    Eur J Pharm Biopharm; 2021 Sep; 166():126-134. PubMed ID: 34153451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceptability of Multiple Uncoated Minitablets in Infants and Toddlers: A Randomized Controlled Trial.
    Klingmann V; Linderskamp H; Meissner T; Mayatepek E; Moeltner A; Breitkreutz J; Bosse HM
    J Pediatr; 2018 Oct; 201():202-207.e1. PubMed ID: 29960767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acceptability of Uncoated Mini-Tablets in Neonates--A Randomized Controlled Trial.
    Klingmann V; Seitz A; Meissner T; Breitkreutz J; Moeltner A; Bosse HM
    J Pediatr; 2015 Oct; 167(4):893-896.e2. PubMed ID: 26259675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceptability of Mini-Tablets in Young Children: Results from Three Prospective Cross-over Studies.
    Klingmann V
    AAPS PharmSciTech; 2017 Feb; 18(2):263-266. PubMed ID: 27714698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable acceptance of mini-tablets compared with syrup: a randomized controlled trial in infants and preschool children.
    Klingmann V; Spomer N; Lerch C; Stoltenberg I; Frömke C; Bosse HM; Breitkreutz J; Meissner T
    J Pediatr; 2013 Dec; 163(6):1728-1732.e1. PubMed ID: 23972645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acceptability of an orodispersible film compared to syrup in neonates and infants: A randomized controlled trial.
    Klingmann V; Pohly CE; Meissner T; Mayatepek E; Möltner A; Flunkert K; Breitkreutz J; Bosse HM
    Eur J Pharm Biopharm; 2020 Jun; 151():239-245. PubMed ID: 32348882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the Acceptability, Swallowability, and Palatability of Film-Coated Mini-Tablet Formulation in Young Children: Results from an Open-Label, Single-Dose, Cross-Over Study.
    Münch J; Sessler I; Bosse HM; Wargenau M; Dreesen JD; Loforese G; Webb NJA; Sivasubramanian R; Reidemeister S; Lustenberger P; Klingmann V
    Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptability, Swallowability, Palatability, and Safety of Multiple Film-Coated Mini-Tablets in Children Aged ≥2-<7 Years: Results of an Open-Label Randomised Study.
    Münch J; Kloft C; Farhan M; Fishman V; Leng S; Bosse HM; Klingmann V
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36840023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study.
    Spomer N; Klingmann V; Stoltenberg I; Lerch C; Meissner T; Breitkreutz J
    Arch Dis Child; 2012 Mar; 97(3):283-6. PubMed ID: 22253279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safe, swallowable and palatable paediatric mini-tablet formulations for a WHO model list of essential medicines for children compound - A promising starting point for future PUMA applications.
    Freerks L; Sommerfeldt J; Löper PC; Klein S
    Eur J Pharm Biopharm; 2020 Nov; 156():11-19. PubMed ID: 32871197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acceptability of different oral formulations in infants and preschool children.
    van Riet-Nales DA; de Neef BJ; Schobben AF; Ferreira JA; Egberts TC; Rademaker CM
    Arch Dis Child; 2013 Sep; 98(9):725-31. PubMed ID: 23853004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects.
    van Riet-Nales DA; Schobben AF; Vromans H; Egberts TC; Rademaker CM
    Arch Dis Child; 2016 Jul; 101(7):662-9. PubMed ID: 26979250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Composite Endpoint for Acceptability Evaluation of Oral Drug Formulations in the Pediatric Population.
    Wargenau M; Reidemeister S; Klingmann I; Klingmann V
    Ther Innov Regul Sci; 2022 Nov; 56(6):903-909. PubMed ID: 35471561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and evaluation of age-appropriate film-coated tablets of levamisole for paediatric use (2 - 18 years).
    Kreeftmeijer-Vegter AR; de Meijer M; Wegman KA; van Veldhuizen CK
    Expert Opin Drug Deliv; 2013 Mar; 10(3):293-300. PubMed ID: 23289762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods of administering oral formulations and child acceptability.
    van Riet-Nales DA; Ferreira JA; Schobben AF; de Neef BJ; Egberts TC; Rademaker CM
    Int J Pharm; 2015 Aug; 491(1-2):261-7. PubMed ID: 26143234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Formulations: Standards and Novel Strategies for Drug Administration in Pediatrics.
    Thabet Y; Klingmann V; Breitkreutz J
    J Clin Pharmacol; 2018 Oct; 58 Suppl 10():S26-S35. PubMed ID: 30248193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-appropriate and acceptable paediatric dosage forms: Insights into end-user perceptions, preferences and practices from the Children's Acceptability of Oral Formulations (CALF) Study.
    Ranmal SR; Cram A; Tuleu C
    Int J Pharm; 2016 Nov; 514(1):296-307. PubMed ID: 27863675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acceptability of different oral dosage forms in paediatric patients in hospital setting.
    Pokharkar V; Sajith M; Vallet T; Akshantal S; Shah R; Ruiz F; Salunke S
    Arch Dis Child; 2022 Sep; 107(9):796-801. PubMed ID: 34799375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.